- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05884242
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
March 28, 2025 updated by: Janssen Research & Development, LLC
Intervention Specific Appendix to PLATFORMPBNAP1001: Evaluation of The Effect of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
The purpose of the study is to characterize the inflammatory response to lipopolysaccharide (LPS; molecules that contains fats and carbohydrates) in the presence of a targeted immune pathway modulator.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Merksem, Belgium, 2170
- Clinical Pharmacology Unit
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- A female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 5 months after adalimumab administration
- A female participant must agree not to be pregnant or planning to become pregnant while enrolled in this study or within 5 months after the last dose of adalimumab
- Must agree not to receive any vaccinations (including those authorized for emergency use, for example, Coronavirus disease-19 (COVID-19) within 2 weeks after study intervention administration
- A male participant must agree not to plan to father a child while enrolled in this study or within 90 days after the last dose of study intervention
- Has a negative severe acute respiratory syndrome coronavirus 2 (COVID-19) reverse transcription-polymerase chain reaction test within 72 hours prior to adalimumab administration on Day 1
- Otherwise healthy on the basis of physical examination, medical history, and vital signs, and 12-lead electrocardiogram (ECG) performed at screening. Any abnormalities must be considered not clinically significant or consistent with the underlying illness in the study population, as specified in the applicable intervention specific appendix (ISA), and this determination must be recorded in the participant's source documents and initiated by the investigator
- Otherwise healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, blood coagulation, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initiated by the investigator
Exclusion Criteria:
- Has a history of congestive heart failure or chronic obstructive pulmonary disease
- Has a history of central or peripheral nervous system demyelinating disease (for example, multiple sclerosis, optic neuritis, or including Guillain-Barre syndrome, respectively)
- Has surgery planned within 10 weeks after the study intervention administration
- Known allergies, hypersensitivity, or intolerance to adalimumab or its excipients
- Had major illness or surgery, (for example, requiring general anesthesia) within 24 weeks before screening, or will not have fully recovered from illness or surgery, or has surgery planned during the time the participant is expected to participate in the study and up to 10 weeks after administration of the study intervention
- History of liver or renal insufficiency significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances, unless consistent with the underlying disease of interest in the study population, if applicable
- History of any type of immunodeficiency or autoimmune disease or disease treatment associated with immune suppression or lymphopenia, unless consistent with the underlying disease of interest in the study population, if applicable. These include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenia and chronic granulomatous disease
- Has an active, acute, or chronic infection
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge
Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6.
|
Adalimumab will be administered subcutaneously.
Other Names:
LPS will be administered intravenously.
|
|
Experimental: Control Arm: LPS Challenge
Participants will receive LPS IV injection on Day 6.
No study interaction will be administered.
|
LPS will be administered intravenously.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in C-reactive Protein (CRP)
Time Frame: From baseline up to Day 14
|
Change from the baseline in CRP levels will be reported.
|
From baseline up to Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline Tumour Necrosis Factor-alpha (TNF-alpha)
Time Frame: From baseline up to Day 14
|
Change from baseline in TNF-alpha levels will be reported.
|
From baseline up to Day 14
|
|
Longitudinal Change From Baseline in Temperature
Time Frame: From baseline up to Day 14
|
Longitudinal change from baseline in temperature [skin] will be reported.
|
From baseline up to Day 14
|
|
Longitudinal Change From Baseline in Heart Rate
Time Frame: From baseline up to Day 14
|
Longitudinal change from baseline in heart rate will be reported.
|
From baseline up to Day 14
|
|
Longitudinal Change From Baseline in Blood Pressure
Time Frame: From baseline up to Day 14
|
Longitudinal change from baseline in blood pressure will be reported.
|
From baseline up to Day 14
|
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to Day 21 (end of study)
|
Percentage of participants with TEAEs through Day 14 will be reported.
An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the intervention under study.
TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
|
Up to Day 21 (end of study)
|
|
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Time Frame: Up to Day 21 (end of study)
|
Percentage of participants with treatment-emergent SAEs will be reported.
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly.
Treatment-emergent SAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.
|
Up to Day 21 (end of study)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 22, 2023
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
August 7, 2023
Study Registration Dates
First Submitted
May 22, 2023
First Submitted That Met QC Criteria
May 22, 2023
First Posted (Actual)
June 1, 2023
Study Record Updates
Last Update Posted (Actual)
March 30, 2025
Last Update Submitted That Met QC Criteria
March 28, 2025
Last Verified
March 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR109299
- 2022-002896-13 (EudraCT Number)
- NOPRODPBNAP1001 (Other Identifier: Janssen Research & Development, LLC)
- PLATFORMPBNAP1001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.